Pharmacodynamics Δ4-Tibolone, one of the active metabolites of<unk> .<unk>  possesses a complex pharmacology and has weak estrogenic, progestogenic, and androgenic activity.<unk> , 3α-hydroxytibolone, and 3β-hydroxytibolone act as agonists of the estrogen receptors.<unk>  and its metabolite δ4-tibolone act as agonists of the progesterone and androgen receptors, while 3α-hydroxytibolone and 3β-hydroxytibolone, conversely, act as antagonists of these receptors. Relative to other progestins,<unk> , including its metabolites, has been described as possessing moderate functional antiestrogenic activity (that is, progestogenic activity), moderate estrogenic activity, high androgenic activity, and no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity. The ovulation-inhibiting dosage of<unk>  is 2.5 mg/day. Estrogenic activity<unk>  and its two major active metabolites, 3α-hydroxytibolone and 3β-hydroxytibolone, act as potent, fully activating agonists of the estrogen receptor (ER), with a high preference for the ERα. These estrogenic metabolites of<unk>  have much weaker activity as estrogens than estradiol (e.g., have 3–29% of the affinity of estradiol for the ), but occur at relatively high concentrations that are sufficient for full and marked estrogenic responses to occur. The estrogenic effects of<unk>  show tissue selectivity in their distribution, with desirable effects in bone, the brain, and the vagina, and lack of undesirable action in the uterus, breast, and liver. The observations of tissue selectivity with<unk>  have been theorized to be the result of metabolism, enzyme modulation (e.g., of estrogen sulfatase and estrogen sulfotransferase), and receptor modulation that vary in different target tissues. This selectivity differs mechanistically from that of selective estrogen receptor modulators (SERMs) such as tamoxifen, which produce their tissue selectivity via means of modulation of the ER. As such, to distinguish it from SERMs,<unk>  has been variously described as a "selective tissue estrogenic activity regulator" (STEAR), "selective estrogen enzyme modulator" (SEEM), or "tissue-specific receptor and intracrine mediator" (TRIM). More encompassingly,<unk>  has also been described as a "selective progestogen, estrogen, and androgen regulator" (SPEAR), which is meant to reflect the fact that it is tissue-selective and that it regulates effects not only of estrogens but of all three of the major sex hormone classes. Although indications of tissue selectivity with<unk>  have been observed, the medication has paradoxically nonetheless been associated with increased risk of endometrial cancer and breast cancer in clinical studies. It was reported in 2002 that<unk>  or its metabolite δ4-tibolone is transformed by aromatase into the potent estrogen 7α-methylethinylestradiol in women, analogously to the transformation of norethisterone into ethinylestradiol. Controversy and disagreement followed when other researchers contested the findings however. By 2008, these researchers had asserted that<unk>  is not aromatized in women and that the previous findings of 7α-methylethinylestradiol detection were merely a methodological artifact. In accordance, a 2009 study found that an aromatase inhibitor had no effect on the estrogenic potencies of<unk>  or its metabolites in vitro, unlike the case of testosterone. In addition, another 2009 study found that the estrogenic effects of<unk>  on adiposity in rats do not require aromatization (as indicated by the use of aromatase knockout mice), further in support that 3α-hydroxytibolone and 3β-hydroxytibolone are indeed responsible for such effects. These findings are also in accordance with the fact that<unk>  decreases sex hormone-binding globulin (SHBG) levels by 50% in women and does not increase the risk of venous thromboembolism (VTE) ( = 0.92), which would not be expected if the medication formed a potent, liver metabolism-resistant estrogen similar to ethinylestradiol in important quantities. (For comparison, combined oral contraceptives containing ethinylestradiol, due mostly or completely to the estrogen component, have been found to increase SHBG levels by 200 to 400% and to increase the risk of VTE by about 4-fold ( = 4.03).) In spite of the preceding, others have held, as recently as 2011, that<unk>  is converted into 7α-methylethinylestradiol in small quantities. They have claimed that 19-nortestosterone derivatives like<unk> , due to lacking a C19 methyl group, indeed are not substrates of the classical aromatase enzyme, but instead are still transformed into the corresponding estrogens by other cytochrome P450 monooxygenases. In accordance, the closely structurally related AAS trestolone (7α-methyl-19-nortestosterone or 17α-desethynyl-δ4-tibolone) has been found to be transformed into 7α-methylestradiol by human placental microsomes in vitro. Also in accordance, considerably disproportionate formation of ethinylestradiol occurs when norethisterone is taken orally (and hence undergoes first-pass metabolism in the liver) relative to parenterally, despite the absence of aromatase in the adult human liver. Progestogenic activity<unk>  and δ4-tibolone act as agonists of the progesterone receptor (PR).<unk>  has low affinity of 6% of that of promegestone for the PR, while δ4-tibolone has high affinity of 90% of that of promegestone for the PR. In spite of its high affinity for the PR however, δ4-tibolone possesses only weak progestogenic activity, about 13% of that of norethisterone. The weak progestogenic activity of<unk>  may not be sufficient to fully counteract estrogenic activity of<unk>  in the uterus and may be responsible for the increased risk of endometrial cancer that has been observed with<unk>  in women in large cohort studies. Androgenic activity<unk> , mainly via δ4-tibolone, has androgenic activity. Whereas<unk>  itself has only about 6% of the affinity of metribolone for the androgen receptor, δ4-tibolone has relatively high affinity of about 35% of the affinity of metribolone for this receptor. At typical clinical dosages in women, the androgenic effects of<unk>  are weak. However, relative to other 19-nortestosterone progestins, the androgenic activity of<unk>  is high, with a potency comparable to that of testosterone. Indeed, the androgenic effects of<unk>  have been ranked as stronger than those of all other commonly used 19-nortestosterone progestins (e.g., norethisterone, levonorgestrel, others). The androgenic effects of<unk>  have been postulated to be involved in the reduced breast cell proliferation, reduced breast cancer risk, improvement in sexual function, less unfavorable changes in hemostatic parameters relative to estrogen–progestogen combinations, and changes in liver protein synthesis (e.g., 30% reductions in HDL cholesterol levels, 20% reduction in triglyceride levels, and 50% reduction in SHBG levels) observed with<unk> . They are also responsible for the androgenic side effects of<unk>  such as acne and increased hair growth in some women. Other activities<unk> , 3α-hydroxytibolone, and 3β-hydroxytibolone act as antagonists of the glucocorticoid and mineralocorticoid receptors, with preference for the mineralocorticoid receptor. However, their affinities for these receptors are low, and<unk>  has been described as possessing no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity. Pharmacokinetics<unk>  metabolism. The mean oral bioavailability of<unk>  is 92%. Its plasma protein binding is 96.3%. It is bound to albumin, and both<unk>  and its metabolites have low affinity for SHBG.<unk>  is metabolized in the liver and intestines. It is a prodrug and is rapidly transformed into several metabolites, including δ4-tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone, as well as sulfate conjugates of these metabolites. 3α-Hydroxytibolone is formed by 3α-hydroxysteroid dehydrogenase, 3β-hydroxytibolone is formed by 3β-hydroxysteroid dehydrogenase, δ4-tibolone is formed by Δ5-4-isomerase, and the sulfate conjugates of<unk>  and its metabolites are formed by sulfotransferases, mainly SULT2A1. The sulfate conjugates can be transformed back into free steroids by steroid sulfatase. Following a single oral dose of 2.5 mg<unk> , peak serum levels of<unk>  were 1.6 ng/mL, of δ4-tibolone were 0.8 ng/mL, of 3α-hydroxytibolone were 16.7 ng/mL, and of 3β-hydroxytibolone were 3.7 ng/mL after 1 to 2 hours. The elimination half-life of<unk>  is 45 hours. It is excreted in urine 40% and feces 60%.
Tibolone
Quinbolone
Oxendolone
Diprobase
Oxytetracycline
Aminophenazone
Sulfadiazine
Revefenacin